Format
Sort by
Items per page

Send to

Choose Destination

Links from Gene

Items: 1 to 20 of 1782

1.

Biological Aspects of mTOR in Leukemia.

Mirabilii S, Ricciardi MR, Piedimonte M, Gianfelici V, Bianchi MP, Tafuri A.

Int J Mol Sci. 2018 Aug 14;19(8). pii: E2396. doi: 10.3390/ijms19082396. Review.

2.

mTOR and Tumor Cachexia.

Duval AP, Jeanneret C, Santoro T, Dormond O.

Int J Mol Sci. 2018 Jul 30;19(8). pii: E2225. doi: 10.3390/ijms19082225. Review.

3.

mTOR-Related Brain Dysfunctions in Neuropsychiatric Disorders.

Ryskalin L, Limanaqi F, Frati A, Busceti CL, Fornai F.

Int J Mol Sci. 2018 Jul 30;19(8). pii: E2226. doi: 10.3390/ijms19082226. Review.

4.

Varicella-zoster virus inhibits autophagosome-lysosome fusion and the degradation stage of mTOR-mediated autophagic flux.

Graybill C, Morgan MJ, Levin MJ, Lee KS.

Virology. 2018 Sep;522:220-227. doi: 10.1016/j.virol.2018.07.018. Epub 2018 Jul 24.

PMID:
30053655
5.

Role of mTOR in Glucose and Lipid Metabolism.

Mao Z, Zhang W.

Int J Mol Sci. 2018 Jul 13;19(7). pii: E2043. doi: 10.3390/ijms19072043. Review.

6.

Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy.

Winters BR, Vakar-Lopez F, Brown L, Montgomery B, Seiler R, Black PC, Boormans JL, Dall Era M, Davincioni E, Douglas J, Gibb EA, van Rhijn BWG, van der Heijden MS, Hsieh AC, Wright JL, Lam HM.

Urol Oncol. 2018 Jul;36(7):342.e7-342.e14. doi: 10.1016/j.urolonc.2018.03.016. Epub 2018 Apr 12.

7.

mTORC1 and mTORC2 Expression Levels in Oral Squamous Cell Carcinoma: An Immunohistochemical and Clinicopathological Study.

Kawasaki G, Naruse T, Furukawa K, Umeda M.

Anticancer Res. 2018 Mar;38(3):1623-1628.

PMID:
29491094
8.

mTOR signaling in stem and progenitor cells.

Meng D, Frank AR, Jewell JL.

Development. 2018 Jan 8;145(1). pii: dev152595. doi: 10.1242/dev.152595. Review.

9.

mTOR-Dependent Cell Proliferation in the Brain.

Ryskalin L, Lazzeri G, Flaibani M, Biagioni F, Gambardella S, Frati A, Fornai F.

Biomed Res Int. 2017;2017:7082696. doi: 10.1155/2017/7082696. Epub 2017 Nov 13. Review.

10.

Mammalian target of rapamycin signaling is a mechanistic link between increased endoplasmic reticulum stress and autophagy in the placentas of pregnancies complicated by growth restriction.

Hung TH, Hsieh TT, Wu CP, Li MJ, Yeh YL, Chen SF.

Placenta. 2017 Dec;60:9-20. doi: 10.1016/j.placenta.2017.10.001. Epub 2017 Oct 9.

PMID:
29208245
11.

mTOR intersects antibody-inducing signals from TACI in marginal zone B cells.

Sintes J, Gentile M, Zhang S, Garcia-Carmona Y, Magri G, Cassis L, Segura-Garzón D, Ciociola A, Grasset EK, Bascones S, Comerma L, Pybus M, Lligé D, Puga I, Gutzeit C, He B, DuBois W, Crespo M, Pascual J, Mensa A, Aróstegui JI, Juan M, Yagüe J, Serrano S, Lloreta J, Meffre E, Hahne M, Cunningham-Rundles C, Mock BA, Cerutti A.

Nat Commun. 2017 Nov 13;8(1):1462. doi: 10.1038/s41467-017-01602-4.

12.

Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer.

Le Rhun E, Bertrand N, Dumont A, Tresch E, Le Deley MC, Mailliez A, Preusser M, Weller M, Revillion F, Bonneterre J.

Eur J Cancer. 2017 Dec;87:189-198. doi: 10.1016/j.ejca.2017.10.006. Epub 2017 Nov 2.

PMID:
29103666
13.

mTOR: A Key to Both Pulmonary Vessel Remodeling and Right Ventricular Function in Pulmonary Arterial Hypertension?

Houssaini A, Adnot S.

Am J Respir Cell Mol Biol. 2017 Nov;57(5):509-511. doi: 10.1165/rcmb.2017-0245ED. No abstract available.

PMID:
29090958
14.

High mTOR expression independently prognosticates poor clinical outcome to induction chemotherapy in acute lymphoblastic leukemia.

Khanna A, Bhushan B, Chauhan PS, Saxena S, Gupta DK, Siraj F.

Clin Exp Med. 2018 May;18(2):221-227. doi: 10.1007/s10238-017-0478-x. Epub 2017 Oct 26.

PMID:
29076004
15.

mTOR Kinase Inhibition Effectively Decreases Progression of a Subset of Neuroendocrine Tumors that Progress on Rapalog Therapy and Delays Cardiac Impairment.

Orr-Asman MA, Chu Z, Jiang M, Worley M, LaSance K, Koch SE, Carreira VS, Dahche HM, Plas DR, Komurov K, Qi X, Mercer CA, Anthony LB, Rubinstein J, Thomas HE.

Mol Cancer Ther. 2017 Nov;16(11):2432-2441. doi: 10.1158/1535-7163.MCT-17-0058. Epub 2017 Sep 1.

16.

Cap-independent translation ensures mTOR expression and function upon protein synthesis inhibition.

Marques-Ramos A, Candeias MM, Menezes J, Lacerda R, Willcocks M, Teixeira A, Locker N, Romão L.

RNA. 2017 Nov;23(11):1712-1728. doi: 10.1261/rna.063040.117. Epub 2017 Aug 18.

17.

mTOR Signaling Confers Resistance to Targeted Cancer Drugs.

Guri Y, Hall MN.

Trends Cancer. 2016 Nov;2(11):688-697. doi: 10.1016/j.trecan.2016.10.006. Epub 2016 Nov 4. Review.

PMID:
28741507
18.

Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer.

Audet-Walsh É, Dufour CR, Yee T, Zouanat FZ, Yan M, Kalloghlian G, Vernier M, Caron M, Bourque G, Scarlata E, Hamel L, Brimo F, Aprikian AG, Lapointe J, Chevalier S, Giguère V.

Genes Dev. 2017 Jun 15;31(12):1228-1242. doi: 10.1101/gad.299958.117. Epub 2017 Jul 19.

19.

mTORC2 regulates hedgehog pathway activity by promoting stability to Gli2 protein and its nuclear translocation.

Maiti S, Mondal S, Satyavarapu EM, Mandal C.

Cell Death Dis. 2017 Jul 13;8(7):e2926. doi: 10.1038/cddis.2017.296.

20.

Targeting the mTOR pathway in breast cancer.

Liu J, Li HQ, Zhou FX, Yu JW, Sun L, Han ZH.

Tumour Biol. 2017 Jun;39(6):1010428317710825. doi: 10.1177/1010428317710825. Review.

PMID:
28639903

Supplemental Content

Support Center